2022
Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroup
2020
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Danne T, Tamborlane WV, Malievsky OA, Franco DR, Kawamura T, Demissie M, Niemoeller E, Goyeau H, Wardecki M, Battelino T. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial. Diabetes Care 2020, 43: 1512-1519. PMID: 32430458, PMCID: PMC7305011, DOI: 10.2337/dc19-1926.Peer-Reviewed Original Research
2019
Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes
Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA. Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 493-498. PMID: 31287721, PMCID: PMC6708264, DOI: 10.1089/dia.2019.0142.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringCGM useDiabetes managementDiabetes careBenefits of CGMYoung childrenGlucose monitoringMean child ageChildren's diabetes careType 1 diabetes managementPainful insertionT1D durationParents of childrenGlucose excursionsImproved sleepClinical strategiesSemistructured qualitative interviewsType 1Parental comfortChild's ageChildrenBehavioural supportMultiple barriersParents' experiencesCaregiversContinuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 4356-4364. PMID: 31127824, PMCID: PMC7296129, DOI: 10.1210/jc.2018-02763.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringMedian timeAge groupsProspective studyNondiabetic individualsGlucose levelsAverage glucoseNonobese body mass indexT1D Exchange Clinic NetworkContinuous glucose monitoring (CGM) profilesInsulin-requiring patientsMulticenter prospective studyBody mass indexDifferent age groupsNondiabetic childrenNondiabetic populationGlycemic profileMass indexNondiabetic participantsGlycemic variabilityMean glucoseClinic networkCGM metricsGlycemic metricsGlucose monitoringRisk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stage
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesInternational Consensus on Use of Continuous Glucose Monitoring
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.Peer-Reviewed Original ResearchContinuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial
Galderisi A, Facchinetti A, Steil GM, Ortiz-Rubio P, Cavallin F, Tamborlane WV, Baraldi E, Cobelli C, Trevisanuto D. Continuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics 2017, 140: e20171162. PMID: 28916591, DOI: 10.1542/peds.2017-1162.Peer-Reviewed Original ResearchConceptsVery preterm infantsGlucose infusion rateContinuous glucose monitoringPreterm infantsCGM groupPercentage of timeEuglycemic rangeSevere hyperglycemiaSevere hypoglycemiaGlycemic variabilityGlucose monitoringCare blood glucose monitoringUse of CGMPoor neurologic outcomeImpaired glucose controlBlood glucose monitoringBlood glucose determinationNeurologic outcomeSecondary outcomesInsulin titrationPrimary outcomeWeeks' gestationControlled TrialsGlucose controlBirth weight
2016
Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes
Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi‐Klug R. Barriers to participation in industry‐sponsored clinical trials in pediatric type 2 diabetes. Pediatric Diabetes 2016, 18: 574-578. PMID: 27807915, DOI: 10.1111/pedi.12465.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttitude of Health PersonnelChildDiabetes Mellitus, Type 2Drug ApprovalDrug IndustryDrugs, InvestigationalEndocrinologyHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInternetNeeds AssessmentPatient SelectionPediatricsRandomized Controlled Trials as TopicResearch PersonnelResearch Support as TopicSocieties, ScientificSurveys and QuestionnairesUnited StatesUnited States Food and Drug AdministrationWorkforceConceptsPediatric Endocrine SocietyType 2 diabetesClinical trialsPediatric endocrinologistsIndustry-sponsored clinical trialsPatients age 18 yearsPediatric type 2 diabetesCurrent glycemic controlNew T2D casesAdditional treatment optionsAge 18 yearsBaseline demographicsT2D patientsGlycemic controlMedication useMultiple medicationsPediatric patientsResearch nursesPediatric populationTreatment optionsEndocrine SocietyT2D casesDrug AdministrationVisit scheduleAnonymous online surveyClinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study
Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, Klingensmith GJ, Gal RL, Silverstein J, Lee J, Redondo MJ, Beck RW, Consortium F. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatric Diabetes 2016, 18: 566-573. PMID: 27758023, PMCID: PMC5397378, DOI: 10.1111/pedi.12459.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDisease ProgressionDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinInsulin SecretionInsulin-Secreting CellsMaleProspective StudiesRiskSeverity of Illness IndexUnited StatesConceptsType 1 diabetesPercentage of participantsClinical outcomesDiabetic ketoacidosisGlycemic controlResidual endogenous insulin secretionCourse of T1D.Pediatric Diabetes ConsortiumYears of diabetesOnset StudyEndogenous insulin secretionOptimal glycemic controlTime of diagnosisDuration of T1DNew insulin analoguesNovel treatment strategiesAdjunctive pharmacologic agentsFirst yearPartial remissionDiabetes CenterInsulin doseYears postdiagnosisMonths postdiagnosisGlycated hemoglobinPharmacologic agentsMitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation periodA cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry
Nambam B, Silverstein J, Cheng P, Ruedy KJ, Beck RW, Wadwa R, Klingensmith G, Willi SM, Wood JR, Bacha F, Thomas IH, Tamborlane WV, Consortium F. A cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry. Pediatric Diabetes 2016, 18: 222-229. PMID: 26970319, DOI: 10.1111/pedi.12377.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChildCohort StudiesCombined Modality TherapyComorbidityCross-Sectional StudiesDiabetes Mellitus, Type 2Glycated HemoglobinHumansHyperglycemiaHypoglycemiaMedical RecordsPractice Patterns, Physicians'PrevalenceRegistriesRisk FactorsUnited StatesYoung Adult
2015
Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.Peer-Reviewed Original ResearchConceptsEarly-onset type 1 diabetesType 1 diabetesBlood glucose levelsWhite matter volumeGlucose levelsMatter volumeTime pointsBrain volumeAge-matched control subjectsCortical gray matter volumeMeasures of hyperglycemiaMean HbA1c levelCurrent treatment guidelinesManagement of diabetesRapid brain maturationGray matter volumeTime of scanCortical surface areaHbA1c levelsTreatment guidelinesControl subjectsGlycemic variationsLongitudinal time pointsBrain maturationDiabetesImproved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injections
2014
Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia
Mauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL. Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes 2014, 64: 1770-1779. PMID: 25488901, PMCID: PMC4407847, DOI: 10.2337/db14-1445.Peer-Reviewed Original ResearchConceptsWhite matter growthControl subjectsAge-matched control subjectsType 1 diabetesHigh-resolution structural MRIWhite matter areasWhite matter volumeYoung childrenContinuous glucose monitoringGray matter regionsNondiabetic childrenChronic hyperglycemiaExecutive function scoresFunction scoresGlucose variabilityMatter volumeChildren ages 4Comprehensive neurocognitive testsBrain regionsLongitudinal assessmentType 1Structural MRIHyperglycemiaDiabetesMatter regionsGlycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D'Souza DN, Rees TM. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验. Journal Of Diabetes 2014, 7: 270-278. PMID: 24734891, DOI: 10.1111/1753-0407.12162.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringChinaCross-Over StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Double-Blind MethodFemaleFollow-Up StudiesHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulin AspartInsulin Infusion SystemsInsulin LisproMalePostprandial PeriodPrognosisRisk FactorsConceptsContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseTreatment periodCross-over designBlood glucoseDay 6Insulin aspartInsulin lisproMean total daily insulin doseTotal daily insulin doseTotal hypoglycemia rateDaily insulin dosePrimary efficacy measureType 1 DMMean blood glucoseSubcutaneous insulin infusionType 1 diabetesHypoglycemia ratesInsulin doseRandomized trialsEfficacy measuresSMBG profilesInsulin infusionDay 1Two-treatment
2013
Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ, Consortium F. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatric Diabetes 2013, 15: 287-293. PMID: 23944865, PMCID: PMC3844085, DOI: 10.1111/pedi.12068.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsIncidenceInfantInsulinKaplan-Meier EstimateMaleProportional Hazards ModelsProspective StudiesUnited StatesConceptsPediatric Diabetes ConsortiumDiabetic ketoacidosisClinical outcomesNatural historyFirst yearCourse of T1DDiagnosis of T1D.Onset of T1DTime of diagnosisSevere hypoglycemic eventsType 1 diabetesMean HbA1cMulticenter studyHypoglycemic eventsClinical measuresLarge cohortIntervention studiesDiagnosisFuture interventionsMonthsOnset StudyHbA1cT1D.T1DOutcomesPediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis
Redondo MJ, Connor CG, Ruedy KJ, Beck RW, Kollman C, Wood JR, Buckingham B, Klingensmith GJ, Silverstein J, Tamborlane WV, Consortium F. Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis. Pediatric Diabetes 2013, 15: 294-302. PMID: 23889707, PMCID: PMC3858510, DOI: 10.1111/pedi.12061.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood Glucose Self-MonitoringChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInfantInsulinMaleNuclear FamilyProspective StudiesSocioeconomic FactorsUnited StatesConceptsPediatric Diabetes ConsortiumLower insulin requirementsBody mass indexDiabetic ketoacidosisInsulin requirementsWhite raceNon-Hispanic white raceDeterminants of hemoglobinOnset of T1DType 1 diabetesLevels one yearHigher socioeconomic statusFirst yearPositive autoantibodiesSD HbA1cNew onsetMass indexBlood glucoseClinical centersDiabetes physiciansPrivate health insuranceTanner stageNumber of visitsFrequent SMBGIntervention studiesSevere hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry
Cengiz E, Xing D, Wong JC, Wolfsdorf JI, Haymond MW, Rewers A, Shanmugham S, Tamborlane WV, Willi SM, Seiple DL, Miller KM, DuBose SN, Beck RW, Network F. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatric Diabetes 2013, 14: 447-454. PMID: 23469984, PMCID: PMC4100244, DOI: 10.1111/pedi.12030.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryDiabetic ketoacidosisSevere hypoglycemiaClinic registryFrequency of SHOccurrence of SHRisk of DKASerious acute complicationsPoor glycemic controlHigh-risk groupAssociation of baselineNew treatment paradigmSeparate logistic regression modelsNon-white raceLower household incomeLogistic regression modelsYoung adult cohortDKA frequencyAcute complicationsClinical factorsGlycemic controlHigher HbA1cT1D ExchangeTreatment paradigmRecommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP)
Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technology & Therapeutics 2013, 15: 198-211. PMID: 23448694, DOI: 10.1089/dia.2013.0051.Peer-Reviewed Original Research